Intellia Therapeutics Inc
$ 11.94
6.23%
07 Aug - close price
- Market Cap 1,668,284,000 USD
- Current Price $ 11.94
- High / Low $ 12.08 / 11.47
- Stock P/E N/A
- Book Value 5.16
- EPS -3.34
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.56 %
- 52 Week High 28.25
- 52 Week Low 7.95
About
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$25.59
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-11 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 |
| Reported EPS | -0.8 | -0.81 | -0.83 | -0.92 | -0.99 | -1.1 | -1.27 | -1.34 | -1.52 | -1.12 | -1.46 | -1.38 |
| Estimated EPS | -0.8 | -0.9 | -0.99 | -0.98 | -1.03 | -1.27 | -1.3164 | -1.37 | -1.2 | -1.36 | -1.44 | -1.5 |
| Surprise | 0 | 0.09 | 0.16 | 0.06 | 0.04 | 0.17 | 0.0464 | 0.03 | -0.32 | 0.24 | -0.02 | 0.12 |
| Surprise Percentage | 0% | 10% | 16.1616% | 6.1224% | 3.8835% | 13.3858% | 3.5248% | 2.1898% | -26.6667% | 17.6471% | -1.3889% | 8% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTLA
2026-08-08 02:39:46
Intellia Therapeutics (NTLA) stock increased by 6.2% following its Q2 earnings report, signaling positive investor sentiment despite continued losses. The company's pipeline progress, particularly with Lonvo-z completing Phase 3 trials and Nex-z trials resuming, is driving optimism. While revenue declined and losses widened year-over-year, the narrowing loss per share and a cash pile providing runway into 2028 are key factors in the investment debate.
2026-08-07 18:39:46
State Street Corporation has disclosed a significant stake in Intellia Therapeutics (NTLA), reporting beneficial ownership of 9,234,987 shares, which represents 6.8% of the outstanding common stock. The filing, a Schedule 13G, indicates that State Street, along with its investment advisory subsidiaries, holds shared voting power over 8,907,136 shares and shared dispositive power over all 9,234,987 shares. This disclosure provides transparency regarding State Street's passive investment in Intellia Therapeutics.
2026-08-07 18:11:20
This article states that Intellia Therapeutics has filed a SCHEDULE 13G form with the SEC. The filing is categorized under "Others," indicating the nature of the report. This type of filing typically discloses beneficial ownership of shares.
2026-08-07 16:01:00
Intellia Therapeutics, Inc. announced that on August 1, 2026, it awarded inducement grants to eight new employees. These grants consisted of time-based restricted stock units (RSUs) for a total of 38,200 shares of Intellia’s common stock, vesting annually over three years, and were made under Intellia’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for employment with the biopharmaceutical company.
2026-08-07 15:11:20
Revolution Medicines' pancreatic cancer drug daraxonrasib is seeing "significant demand" through a compassionate use program, leading analysts to raise sales projections. Intellia Therapeutics believes it has identified a genetic signature (HLA C*05:01 allele) linked to liver enzyme elevations in patients receiving its experimental gene editing treatment nex-z, potentially resolving a key safety concern. The article also provides updates on Arrowhead Pharmaceuticals' acquisition of a priority review voucher, a joint manufacturing facility between CSPC Pharmaceutical and AstraZeneca, and Vedanta Biosciences' new funding for a C. difficile trial.
2026-08-07 08:30:00
Evercore ISI upgraded Intellia Therapeutics (NTLA) to Outperform, citing promising new data on its rare-disease therapy, nex-z, developed in partnership with Regeneron (REGN). This upgrade led to a premarket rise in Intellia's stock on Friday.
